| 분자 | Cat. No. | Product Name | 종 | Host | 구조 | 순도 | Activity | 규격 및 가격 |
|---|---|---|---|---|---|---|---|---|
| HLA-A*0301 & B2M & KRASG12C (VVGACGVGK) | Biotinylated Human HLA-A*03:01&B2M&KRASG12C (VVGACGVGK) Complex Protein (Monomer, MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $125.00 25ug |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| ACC-006 | ACC-006 | Phase 2 Clinical | Jiangsu Aidea Pharmaceutical Co Ltd, China Pharmaceutical University | Solid tumours; Carcinoma, Non-Small-Cell Lung | 상세 |
| Sulforadex | SFX-01 | Phase 2 Clinical | Evgen Pharma, Lalilab, Pharmagra Labs Inc | Autistic Disorder; Thrombosis; Precancerous Conditions; Ventricular Dysfunction, Left; Subarachnoid Hemorrhage; Lung Neoplasms; Renal Insufficiency, Chronic; Parkinson Disease; Asthma; Hyperplasia; Prostatic Neoplasms; Carcinoma in Situ; Breast Neoplasms; Head and Neck Neoplasms; Small Cell Lung Carcinoma; Kidney Diseases; Heart Diseases; Neoplasms; Neurodevelopmental Disorders; Nasolabial fold wrinkles; Schizophrenia; Anaplasia; Squamous Cell Carcinoma of Head and Neck; Autism Spectrum Disorder; Drug-Related Side Effects and Adverse Reactions; Heart Failure, Diastolic | 상세 |
| NLM-001 | NLM-001 | Phase 2 Clinical | Nelum Corp | Carcinoma, Pancreatic Ductal | 상세 |
| IMP5471-CA | Phase 1 Clinical | Shanghai Impact Pharmaceutical Co Ltd | Hematologic Diseases | 상세 |
